OncoTherapy Science, Inc. (4564.T)
JPY 26.0
(-3.7%)
JPY 26.0
(-3.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 610.11 Million JPY | -46.24% |
| 2022 | 1.13 Billion JPY | -1.63% |
| 2021 | 1.15 Billion JPY | 246.99% |
| 2020 | 332.47 Million JPY | 5.14% |
| 2019 | 316.21 Million JPY | 12.7% |
| 2018 | 280.58 Million JPY | 32.82% |
| 2017 | 211.25 Million JPY | -26.31% |
| 2016 | 286.66 Million JPY | 7.4% |
| 2015 | 266.9 Million JPY | -65.34% |
| 2014 | 769.95 Million JPY | -24.35% |
| 2013 | 1.01 Billion JPY | -68.95% |
| 2012 | 3.27 Billion JPY | -47.34% |
| 2011 | 6.22 Billion JPY | 16.09% |
| 2010 | 5.36 Billion JPY | 1.97% |
| 2009 | 5.25 Billion JPY | 58.0% |
| 2008 | 3.32 Billion JPY | 68.67% |
| 2007 | 1.97 Billion JPY | 145.23% |
| 2006 | 804.49 Million JPY | -30.93% |
| 2005 | 1.16 Billion JPY | -26.28% |
| 2004 | 1.58 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 100 Million JPY | -30.61% |
| 2023 Q3 | 109.55 Million JPY | -47.41% |
| 2023 Q2 | 208.31 Million JPY | 40.62% |
| 2023 Q1 | 148.13 Million JPY | -65.96% |
| 2023 Q4 | 144.11 Million JPY | 31.54% |
| 2023 FY | 610.11 Million JPY | -46.24% |
| 2022 Q3 | 185.12 Million JPY | 43.66% |
| 2022 Q4 | 435.21 Million JPY | 135.09% |
| 2022 FY | 1.13 Billion JPY | -1.63% |
| 2022 Q2 | 128.86 Million JPY | -66.59% |
| 2022 Q1 | 385.7 Million JPY | -52.87% |
| 2021 Q4 | 818.44 Million JPY | 765.1% |
| 2021 Q3 | 94.6 Million JPY | -35.83% |
| 2021 FY | 1.15 Billion JPY | 246.99% |
| 2021 Q2 | 147.42 Million JPY | 58.21% |
| 2021 Q1 | 93.18 Million JPY | -45.94% |
| 2020 Q3 | 59.28 Million JPY | -0.89% |
| 2020 FY | 332.47 Million JPY | 5.14% |
| 2020 Q4 | 172.36 Million JPY | 190.74% |
| 2020 Q1 | 41.01 Million JPY | -73.48% |
| 2020 Q2 | 59.81 Million JPY | 45.85% |
| 2019 Q2 | 48.68 Million JPY | -12.79% |
| 2019 Q3 | 57.07 Million JPY | 17.23% |
| 2019 Q1 | 55.82 Million JPY | 70.63% |
| 2019 FY | 316.21 Million JPY | 12.7% |
| 2019 Q4 | 154.63 Million JPY | 170.94% |
| 2018 Q2 | 10.99 Million JPY | -18.25% |
| 2018 FY | 280.58 Million JPY | 32.82% |
| 2018 Q4 | 32.71 Million JPY | -85.36% |
| 2018 Q1 | 13.45 Million JPY | 66.73% |
| 2018 Q3 | 223.42 Million JPY | 1931.85% |
| 2017 Q1 | 200.91 Million JPY | 287.24% |
| 2017 FY | 211.25 Million JPY | -26.31% |
| 2017 Q4 | 8.06 Million JPY | 353.2% |
| 2017 Q3 | 1.78 Million JPY | 265.5% |
| 2017 Q2 | 487 Thousand JPY | -99.76% |
| 2016 FY | 286.66 Million JPY | 7.4% |
| 2016 Q2 | 33.99 Million JPY | 8527.16% |
| 2016 Q4 | 51.88 Million JPY | -74.11% |
| 2016 Q3 | 200.39 Million JPY | 489.56% |
| 2016 Q1 | 394 Thousand JPY | -99.3% |
| 2015 Q4 | 55.93 Million JPY | 1943.06% |
| 2015 FY | 266.9 Million JPY | -65.34% |
| 2015 Q1 | 206.23 Million JPY | -44.51% |
| 2015 Q2 | 1.98 Million JPY | -99.04% |
| 2015 Q3 | 2.73 Million JPY | 37.73% |
| 2014 Q1 | 304.93 Million JPY | 20.62% |
| 2014 FY | 769.95 Million JPY | -24.35% |
| 2014 Q2 | 46.65 Million JPY | -84.7% |
| 2014 Q3 | 46.69 Million JPY | 0.09% |
| 2014 Q4 | 371.67 Million JPY | 695.99% |
| 2013 Q1 | 211.14 Million JPY | -86.28% |
| 2013 Q3 | 431.26 Million JPY | 251.89% |
| 2013 FY | 1.01 Billion JPY | -68.95% |
| 2013 Q4 | 252.8 Million JPY | -41.38% |
| 2013 Q2 | 122.55 Million JPY | -41.96% |
| 2012 Q2 | 777.45 Million JPY | 119.44% |
| 2012 Q1 | 354.28 Million JPY | -92.57% |
| 2012 FY | 3.27 Billion JPY | -47.34% |
| 2012 Q3 | 606.59 Million JPY | -21.98% |
| 2012 Q4 | 1.53 Billion JPY | 153.73% |
| 2011 Q4 | 4.76 Billion JPY | 894.83% |
| 2011 Q1 | 337.97 Million JPY | -77.89% |
| 2011 Q2 | 640.17 Million JPY | 89.41% |
| 2011 Q3 | 479.14 Million JPY | -25.15% |
| 2011 FY | 6.22 Billion JPY | 16.09% |
| 2010 Q1 | 273.59 Million JPY | -89.5% |
| 2010 Q2 | 1.56 Billion JPY | 473.72% |
| 2010 Q3 | 1.98 Billion JPY | 26.76% |
| 2010 Q4 | 1.52 Billion JPY | -23.19% |
| 2010 FY | 5.36 Billion JPY | 1.97% |
| 2009 Q1 | 296.49 Million JPY | -89.54% |
| 2009 FY | 5.25 Billion JPY | 58.0% |
| 2009 Q4 | 2.6 Billion JPY | 71.74% |
| 2009 Q3 | 1.51 Billion JPY | 81.11% |
| 2009 Q2 | 837.81 Million JPY | 182.57% |
| 2008 FY | 3.32 Billion JPY | 68.67% |
| 2008 Q3 | 270.69 Million JPY | 0.0% |
| 2008 Q4 | 2.83 Billion JPY | 947.09% |
| 2007 FY | 1.97 Billion JPY | 145.23% |
| 2006 FY | 804.49 Million JPY | -30.93% |
| 2005 FY | 1.16 Billion JPY | -26.28% |
| 2004 FY | 1.58 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 87.21% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -440.281% |
| GNI Group Ltd. | 26.01 Billion JPY | 97.654% |
| Linical Co., Ltd. | 12.3 Billion JPY | 95.043% |
| Trans Genic Inc. | 13.08 Billion JPY | 95.337% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 7.773% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 88.172% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 60.9% |
| AnGes, Inc. | 152.98 Million JPY | -298.809% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 95.221% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 25.295% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -350.245% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 62.475% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -42.43% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 67.909% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 10.601% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 74.905% |
| PeptiDream Inc. | 28.71 Billion JPY | 97.875% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -867.857% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -404.23% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -847286.111% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -1429.616% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 86.474% |
| FunPep Company Limited | 530 Thousand JPY | -115016.604% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -781.037% |
| Stella Pharma Corporation | 269.49 Million JPY | -126.396% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -92.577% |
| Cuorips Inc. | 23.1 Million JPY | -2540.975% |
| K Pharma,Inc. | 1 Billion JPY | 38.988% |
| Takara Bio Inc. | 43.5 Billion JPY | 98.598% |
| ReproCELL Incorporated | 2.42 Billion JPY | 74.859% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 64.431% |
| StemCell Institute Inc. | 2.48 Billion JPY | 75.41% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 75.733% |
| CellSeed Inc. | 190.13 Million JPY | -220.888% |